C WorldWide Group Holding A S increased its stake in shares of Puma Biotechnology Inc (NYSE:PBYI) by 19.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,834 shares of the biopharmaceutical company’s stock after buying an additional 6,465 shares during the period. C WorldWide Group Holding A S’s holdings in Puma Biotechnology were worth $3,481,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Strs Ohio acquired a new stake in shares of Puma Biotechnology during the second quarter worth $122,000. Bank of Montreal Can acquired a new stake in shares of Puma Biotechnology during the first quarter worth $195,000. Alambic Investment Management L.P. acquired a new stake in shares of Puma Biotechnology during the first quarter worth $201,000. Fox Run Management L.L.C. acquired a new stake in shares of Puma Biotechnology during the second quarter worth $227,000. Finally, Creative Planning raised its stake in shares of Puma Biotechnology by 62.3% in the second quarter. Creative Planning now owns 2,862 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 1,099 shares during the last quarter. Institutional investors own 80.98% of the company’s stock.

Puma Biotechnology Inc (PBYI) opened at 78.45 on Friday. Puma Biotechnology Inc has a 52 week low of $28.35 and a 52 week high of $98.85. The firm’s market capitalization is $2.90 billion. The stock’s 50 day moving average price is $88.59 and its 200 day moving average price is $56.34.

Puma Biotechnology (NYSE:PBYI) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the consensus estimate of ($1.32) by $0.78. On average, equities analysts expect that Puma Biotechnology Inc will post ($8.63) EPS for the current year.

WARNING: This article was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.watchlistnews.com/c-worldwide-group-holding-a-s-has-3-48-million-position-in-puma-biotechnology-inc-nysepbyi/1478001.html.

A number of equities research analysts have recently weighed in on PBYI shares. Stifel Nicolaus restated a “buy” rating and set a $88.00 price target on shares of Puma Biotechnology in a research note on Wednesday, April 19th. Zacks Investment Research upgraded Puma Biotechnology from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a research note on Tuesday, May 16th. Credit Suisse Group restated an “outperform” rating and set a $58.00 price target on shares of Puma Biotechnology in a research note on Tuesday, April 18th. J P Morgan Chase & Co restated an “overweight” rating and set a $89.00 price target on shares of Puma Biotechnology in a research note on Wednesday, May 24th. Finally, Leerink Swann restated an “outperform” rating and set a $125.00 price target (up previously from $115.00) on shares of Puma Biotechnology in a research note on Wednesday, July 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $109.56.

In other news, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of the firm’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $75.38, for a total value of $93,147,066.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Richard Paul Bryce sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $87.10, for a total value of $435,500.00. Following the completion of the sale, the senior vice president now directly owns 34,237 shares of the company’s stock, valued at $2,982,042.70. The disclosure for this sale can be found here. Insiders sold a total of 2,010,261 shares of company stock valued at $159,425,452 over the last three months. Insiders own 22.70% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NYSE:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.